Aptahem AB is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in patients diagnosed with a septic condition, among others. The company holds patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.

World Sepsis Day

Online event, September 13 2021

Aptahem hosted an online Sepsis Seminar on World Sepsis Day. The presentations are in English, and the full seminar is available here.

Pink-WSD-Sticker-04

GSA-320x260

Aptahem is supporting Global Sepsis Alliance and is part of the World Sepsis Declaration